Edition:
United States

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

0.86USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
69,008
52-wk High
$3.97
52-wk Low
$0.43

Latest Key Developments (Source: Significant Developments)

MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug
7:30am EST 

Dec 13 (Reuters) - MabVax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS.MABVAX THERAPEUTICS HOLDINGS INC - PLANS TO REPORT INTERIM RESULTS FROM STUDY EARLY IN Q1 OF 2018 AND CONTINUE DOSE ESCALATION PHASE OF PROGRAM.  Full Article

MabVax Therapeutics files for resale of 9.7 mln shares‍​
Wednesday, 25 Oct 2017 04:21pm EDT 

Oct 25 (Reuters) - MabVax Therapeutics Holdings Inc : :MabVax Therapeutics Holdings Inc - files for resale of 9.7 million shares of common stock of co by certain stockholders ‍​.  Full Article

MabVax Therapeutics files for resale of up to 6.97 mln shares of co's common stock‍​
Thursday, 19 Oct 2017 05:49pm EDT 

Oct 20 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings Inc files for resale of up to 6.97 million shares of co's common stock‍​ by the selling stockholders - SEC filing‍​.  Full Article

Mabvax Therapeutics starts patient enrollment in phase 1 trial for cancer drug MVT-1075
Wednesday, 11 Oct 2017 08:00am EDT 

Oct 11 (Reuters) - Mabvax Therapeutics Holdings Inc :Mabvax Therapeutics initiates patient enrollment in a phase 1 trial for MVT-1075, a new radioimmunotherapy treatment for advanced pancreatic, colon and lung cancers.Mabvax Therapeutics Holdings Inc - ‍Plans to announce topline interim results before year end from study​.  Full Article

John Stetson discloses 5.64 percent passive stake in MabVax Therapeutics Holdings Inc
Tuesday, 19 Sep 2017 08:22am EDT 

Sept 19 (Reuters) - Mabvax Therapeutics Holdings Inc :John Stetson discloses 5.64 percent passive stake in MabVax Therapeutics Holdings Inc as of September 11, 2017- SEC filing‍​.  Full Article

Mabvax Therapeutics engages Greenhill & co. as advisor for exploring strategic alternatives
Wednesday, 6 Sep 2017 08:05am EDT 

Sept 6 (Reuters) - Mabvax Therapeutics Holdings Inc ::Mabvax Therapeutics engages Greenhill & Co. as advisor for exploring strategic alternatives.Mabvax Therapeutics-‍greenhill to assist co in evaluating options currently being considered & new options including acquisition of mabvax by another co.  Full Article

Mabvax Therapeutics Holdings, Inc. Announces the closing of $1.3 million registered direct offering
Tuesday, 22 Aug 2017 04:05pm EDT 

Aug 22 (Reuters) - Mabvax Therapeutics Holdings Inc :Mabvax Therapeutics Holdings, Inc. Announces the closing of $1.3 million registered direct offering and is engaging an advisory bank to explore strategic alternatives.Mabvax Therapeutics - is engaging a independent investment bank to serve as financial advisor to assist co in exploring, evaluating strategic options​.Mabvax Therapeutics - strategic ‍options currently being considered could include acquisition of co by another company, sale or divestiture of specific assets.  Full Article

MabVax Therapeutics Holdings announces pricing of registered direct offering
Monday, 14 Aug 2017 08:10am EDT 

Aug 14 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings Inc announces pricing of registered direct offering.MabVax Therapeutics - ‍purchase agreements with investors providing for registered sale of about $1.3 million of shares of Series J convertible preferred stock​.MabVax Therapeutics Holdings Inc - ‍registered direct offering represents about 2,386.36 shares at a purchase price of $550 per share​.  Full Article

Mabvax Therapeutics to explore strategic alternatives
Monday, 24 Jul 2017 08:00am EDT 

July 24 (Reuters) - Mabvax Therapeutics Holdings Inc ::Mabvax therapeutics board of directors authorizes the company to explore strategic alternatives.Mabvax therapeutics holdings inc - ‍company to engage advisory firm​.Mabvax - ‍options being considered include acquisition of co by another company, sale or divestiture of specific assets, merging with another company​.  Full Article

Mabvax Therapeutics holdings files for mixed shelf of upto $50 mln
Friday, 14 Jul 2017 04:15pm EDT 

July 14 (Reuters) - Mabvax Therapeutics Holdings Inc :Files for mixed shelf of upto $50 million - SEC filing.  Full Article

BRIEF-MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug

* MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS